JP2007505830A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505830A5
JP2007505830A5 JP2006525902A JP2006525902A JP2007505830A5 JP 2007505830 A5 JP2007505830 A5 JP 2007505830A5 JP 2006525902 A JP2006525902 A JP 2006525902A JP 2006525902 A JP2006525902 A JP 2006525902A JP 2007505830 A5 JP2007505830 A5 JP 2007505830A5
Authority
JP
Japan
Prior art keywords
composition according
particles
composition
hydrophobic amino
mucus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525902A
Other languages
English (en)
Japanese (ja)
Other versions
JP4913595B2 (ja
JP2007505830A (ja
Filing date
Publication date
Priority claimed from GBGB0321611.6A external-priority patent/GB0321611D0/en
Priority claimed from GBGB0327723.3A external-priority patent/GB0327723D0/en
Application filed filed Critical
Publication of JP2007505830A publication Critical patent/JP2007505830A/ja
Publication of JP2007505830A5 publication Critical patent/JP2007505830A5/ja
Application granted granted Critical
Publication of JP4913595B2 publication Critical patent/JP4913595B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006525902A 2003-09-15 2004-09-15 肺疾患を治療するための粘液活性剤 Expired - Fee Related JP4913595B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0321611.6 2003-09-15
GBGB0321611.6A GB0321611D0 (en) 2003-09-15 2003-09-15 Pharmaceutical compositions
GBGB0327723.3A GB0327723D0 (en) 2003-09-15 2003-11-28 Pharmaceutical compositions
GB0327723.3 2003-11-28
PCT/GB2004/003932 WO2005025540A2 (en) 2003-09-15 2004-09-15 Mucoactive agents for treating a pulmonary disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011243533A Division JP2012031204A (ja) 2003-09-15 2011-11-07 肺疾患を治療するための粘液活性剤

Publications (3)

Publication Number Publication Date
JP2007505830A JP2007505830A (ja) 2007-03-15
JP2007505830A5 true JP2007505830A5 (enExample) 2011-08-04
JP4913595B2 JP4913595B2 (ja) 2012-04-11

Family

ID=34315438

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525902A Expired - Fee Related JP4913595B2 (ja) 2003-09-15 2004-09-15 肺疾患を治療するための粘液活性剤
JP2011243533A Pending JP2012031204A (ja) 2003-09-15 2011-11-07 肺疾患を治療するための粘液活性剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011243533A Pending JP2012031204A (ja) 2003-09-15 2011-11-07 肺疾患を治療するための粘液活性剤

Country Status (15)

Country Link
US (2) US7928089B2 (enExample)
EP (2) EP2277505A3 (enExample)
JP (2) JP4913595B2 (enExample)
KR (1) KR20060082865A (enExample)
CN (1) CN1874757B (enExample)
AU (1) AU2004271778B2 (enExample)
BR (1) BRPI0414425A (enExample)
CA (1) CA2538399A1 (enExample)
GB (1) GB0327723D0 (enExample)
IL (1) IL173987A0 (enExample)
NO (1) NO20061254L (enExample)
NZ (1) NZ545550A (enExample)
RU (1) RU2363448C2 (enExample)
SG (1) SG146649A1 (enExample)
WO (1) WO2005025540A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP1694342B1 (en) * 2003-11-12 2020-11-04 Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005112970A2 (en) * 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CA2680413C (en) 2006-03-15 2020-06-09 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat rheumatoid arthritis
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CA2663795A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
CN101433521B (zh) * 2007-11-14 2012-08-08 中国医学科学院药用植物研究所 药用可吸入微粒、使用其的肺部吸入制剂及其制备方法
HUE032875T2 (en) 2008-01-25 2017-11-28 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP2411137B1 (en) 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
TW201306847A (zh) * 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
EP2812031A4 (en) * 2012-02-06 2015-11-04 Univ Iowa Res Found METHOD FOR REGULATING CFTR GENE EXPRESSION AND MOLECULAR MATURATION
SG11201407676VA (en) * 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
ITMI20121052A1 (it) * 2012-06-18 2013-12-19 Ecupharma Srl Formulazioni inalatorie per la rimozione delle secrezioni viscose dall'apparato respiratorio
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SI3191081T1 (sl) 2014-09-09 2020-07-31 Vectura Limited Formulacija, ki vsebuje glikopirolat, postopek in naprava
SG10201902915VA (en) * 2014-10-01 2019-04-29 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
ES2732837T3 (es) 2014-10-10 2019-11-26 Ablynx Nv Dispositivo de inhalación para uso en la terapia con aerosoles de enfermedades respiratorias
EP3204041A1 (en) 2014-10-10 2017-08-16 Ablynx N.V. Methods of treating rsv infections
JP6650933B2 (ja) 2014-10-31 2020-02-19 ベンド リサーチ， インコーポレイテッド マトリックス中に分散された活性薬剤ドメインを形成するためのプロセス
CN105920020B (zh) * 2016-06-23 2019-01-08 潘海英 一种治疗肺部疾病的药物组合物及其制备方法和用途
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
EP3525759A1 (en) * 2016-10-14 2019-08-21 Pulmatrix Operating Company, Inc. Antifungal dry powders
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
TR201722950A2 (tr) * 2017-12-29 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Koah tedavisinde yeni farmasötik bileşimler.
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
US20230038019A1 (en) * 2019-03-18 2023-02-09 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
CA3140641A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
KR102250876B1 (ko) * 2019-07-18 2021-05-11 충북대학교 산학협력단 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물
WO2025034892A2 (en) * 2023-08-07 2025-02-13 The University Of North Carolina At Chapel Hill Ultrasound contrast agent for binding with or adhering to respiratory mucus and methods for using same

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734401A (en) 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
EP0630230B1 (en) 1992-03-10 1996-12-04 FISONS plc Pharmaceutical inhalation compositions
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
AU688272B2 (en) * 1992-07-24 1998-03-12 Paringenix, Inc. Medicameny for inhibiting neutrophil elastase and cathepsin
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
CA2252814A1 (en) 1996-04-29 1997-11-06 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0918461B1 (en) * 1996-07-29 2004-10-27 Paringenix, Inc. Methods of treating asthma with o-desulfated heparin
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
CA2283705A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
US20010046974A1 (en) 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
AU7753898A (en) 1997-06-06 1998-12-21 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CA2209342A1 (en) 1997-06-30 1998-12-30 The University Of British Columbia Use of dextran and other oligomeric saccharides to improve airway clearance
IT1296998B1 (it) 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
US20030118514A1 (en) 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
WO2000059476A1 (en) 1999-04-05 2000-10-12 Pharmaceutical Discovery Corporation Methods for fine powder formation
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US6560897B2 (en) 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
BR0012202A (pt) 1999-06-30 2002-04-02 Hamilton Civic Hospitals Res Composições de heparina de peso molecular médio (mmwh), método de tratamento de uma condição trombótica, método de prevenção da formação de um trombo, método de inibição da formação de trombos, composição farmacêutica, método de tratamento de trombose venosa profunda, método de prevenção de embolia pulmonar, método de preparação e usos de uma composição de mmwh
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
ES2161615B1 (es) 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
HK1047246A1 (zh) 1999-08-26 2003-02-14 艾伯塔大学理事会 带电葡聚糖作为粘液活性剂的用途及有关方法和药物组合物
EP1223915B1 (en) 1999-10-29 2005-12-21 Nektar Therapeutics Dry powder compositions having improved dispersivity
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
CA2340836A1 (en) 2000-03-18 2001-09-18 Degussa Ag Granular product
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20050032745A1 (en) 2000-05-04 2005-02-10 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CN1197587C (zh) 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
EP1296651B2 (en) * 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6969705B2 (en) 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20040109827A1 (en) 2000-11-29 2004-06-10 Satomi Onoue Powdery preparations and proecss for producing the same
WO2002043701A2 (en) 2000-11-30 2002-06-06 Vectura Limited Method of making particles for use in a pharmaceutical composition
US8048451B2 (en) 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
ES2689704T3 (es) 2000-11-30 2018-11-15 Vectura Limited Partículas para usar en una composición farmacéutica
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
CN1481236A (zh) 2000-12-22 2004-03-10 气凝胶粉末治疗剂
GB0102902D0 (en) 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
GB0106403D0 (en) 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
US20030091513A1 (en) 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20050013867A1 (en) 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
EP1992335A1 (en) 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
AU2002366267B2 (en) 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US20060188451A1 (en) 2001-12-21 2006-08-24 Aspen Aerogels, Inc. Aerogel based pharmaceutical formulations
US20030124087A1 (en) 2001-12-26 2003-07-03 Amitie Co. Ltd. Anti-adhesion barrier
DK1513502T3 (en) 2002-02-18 2016-04-11 Ockham Biotech Ltd Combination therapy for airway disorders
ES2315479T5 (es) * 2002-02-18 2015-07-01 Ockham Biotech Limited Empleo de glicosaminoglicanos tales como p.ej. Heparina para el tratamiento de trastornos respiratorios tales como COPD
EP1549337B1 (en) * 2002-02-18 2014-08-13 Ockham Biotech Limited Combination of DNase I and glycosaminoglycans for use in extracellular DNA clearance
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
FI116657B (fi) 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
AU2002308143A1 (en) 2002-04-12 2003-10-27 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US20040028746A1 (en) 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20040043064A1 (en) 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
JP2006503865A (ja) 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
GB0304540D0 (en) 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
US6933372B2 (en) 2003-03-07 2005-08-23 Warner-Lambert Company Method to produce a solid form of heparin
AU2004251623B2 (en) 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
CA2435632A1 (en) 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
JP2007508240A (ja) 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
PT1699434E (pt) 2003-09-02 2011-05-03 Norton Healthcare Ltd Processo para a prepara??o de um medicamento
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
EP1663164A2 (en) * 2003-09-15 2006-06-07 Vectura Limited Methods for preparing pharmaceutical compositions
WO2005032483A2 (en) 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
AU2004285553B2 (en) 2003-10-31 2009-12-10 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
CN1261105C (zh) 2003-12-05 2006-06-28 吉林省辽源亚东药业股份有限公司 一种复方吡拉西坦脑蛋白水解物制剂及制备方法
GB0329208D0 (en) 2003-12-17 2004-01-21 Ici Plc Particulate materials
US7776241B2 (en) 2003-12-23 2010-08-17 Niro A/S Method and apparatus for producing micro particles
US7928059B2 (en) * 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
PT1748781E (pt) 2004-05-27 2013-01-22 Baxter Int Processos para o tratamento de distúrbios de hemorragias utilizando polissacarídeos sulfatados
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
AU2005287397A1 (en) 2004-06-30 2006-03-30 Paul L. Deangelis Methods of selectively treating diseases with specific glycosaminoglycan polymers
WO2006019894A2 (en) 2004-07-14 2006-02-23 O'connor Michael F Nebulized pharmaceutical compositions for the treatment of bronchial disorders
GB0416397D0 (en) 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006026502A1 (en) 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
CN101132769A (zh) 2005-02-10 2008-02-27 奥瑞克索股份公司 用于药物的跨黏膜给药的药物组合物
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US20090186088A1 (en) 2005-03-18 2009-07-23 Nanomaterials Technology Pte Ltd Inhalable drug
BRPI0611433A2 (pt) 2005-05-05 2010-09-08 Sanofi Aventis Us Llc formulações estáveis de nanopartìcula
EP1942912B1 (en) 2005-10-12 2016-12-14 Seikagaku Corporation Agent for applying to mucosa and method for production thereof
US20070098803A1 (en) 2005-10-27 2007-05-03 Primet Precision Materials, Inc. Small particle compositions and associated methods
US7597094B2 (en) * 2005-11-29 2009-10-06 Leon Monroe Pittman Compound bow maintenance press and method for compressing a compound bow from the bow limb ends
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
WO2007075381A2 (en) 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Pharmaceutical compositions of ilaprazole
DE102005062270A1 (de) 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
US20070166386A1 (en) 2006-01-13 2007-07-19 Chinea Vanessa I Nanoparticle formation of pharmaceutical ingredients
WO2007117661A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd, Drug microparticles
WO2007123793A2 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
US20080299210A1 (en) 2006-04-13 2008-12-04 Min Wei Stable nanosized amorphous drug
US20080181957A1 (en) 2006-06-23 2008-07-31 Min Wei Increased amorphous stability of poorly water soluble drugs by nanosizing
WO2008011051A1 (en) 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
US20090203789A1 (en) 2008-01-31 2009-08-13 Multi Formulations Ltd. Fast Dissolution Amino Acid Composition

Similar Documents

Publication Publication Date Title
JP2007505830A5 (enExample)
RU2006112583A (ru) Фармацевтические композиции
JP6141906B2 (ja) スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤
JP5739197B2 (ja) 多孔性微粒子および使用方法
Odziomek et al. Conception, preparation and properties of functional carrier particles for pulmonary drug delivery
Yang et al. Dry powder inhaler formulation of lipid–polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles
ITMI990455A1 (it) Particelle veicolo modificate da utilizzarsi nella preparazione di formulazioni farmaceutiche sotto forma di polimeri per inalazione e loro
Kim et al. Supercritical fluid-micronized ipratropium bromide for pulmonary drug delivery
Cabral et al. Design of experiments approach on the preparation of dry inhaler chitosan composite formulations by supercritical CO2-assisted spray-drying
CN103536583A (zh) 一种原花青素缓释纳米微球及制备方法和应用
WO2012061902A1 (en) Micronised spray-dried particles comprising polymyxin
JP2019517541A5 (enExample)
WO2017042341A1 (en) Jet milling method
Hamedani et al. A novel particle engineering method for the production of inhalable cromolyn sodium powders by a combination of spray drier and nebulizer
Kramek-Romanowska et al. Effects of process variables on the properties of spray-dried mannitol and mannitol/disodium cromoglycate powders suitable for drug delivery by inhalation
Albetawi Current research on spray-dried chitosan nanocomposite microparticles for pulmonary drug delivery
CN105251060A (zh) 一种利用真空冷喷涂技术制备药物缓释涂层的方法及其产品
CN105012278B (zh) 一种干粉吸入粉雾剂载体蔗糖及其制备方法
JP3888753B2 (ja) 持続性粉末状吸入用医薬品組成物
AU2013201437B2 (en) DPI formulation containing sulfoalkyl ether cyclodextrin
JP2023528883A (ja) 呼吸器系傷害改善用医薬組成物及び呼吸器系傷害改善用医薬組成物の製造のための用途
Xu et al. A novel pullulan excipient for inhalable spray-dried powders
EP2340816A1 (en) A plant for manufacturing composite carrier particles
Auriemma et al. Gentamicin and particle engineering: from an old molecule to innovative drug delivery systems
Agarwal et al. Short-Term Pulmonary Toxicity Assessment of Pre-and Post-Incinerated Organomodified Nanoclay in Mice